Panacea Biotec in South Africa

Panacea Biotec’s Strategic Moves and Market Performance

Hyderabad, India – July 30, 2025

Panacea Biotec, a leading Indian biotechnology company, has recently undertaken several strategic initiatives to bolster its global presence and financial standing.

Launch of Generic Cancer Drug in Canada

In October 2023, Panacea Biotec, through its subsidiary Panacea Biotec Pharma Limited and in collaboration with Apotex Inc., introduced a generic version of the cancer drug Abraxane in the Canadian market. This product, Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. The Canadian market for Abraxane was valued at $26.4 million as of September 2023. (thehindu.com)

Patent Settlement with Sanofi

In September 2024, Panacea Biotec reached a settlement with Sanofi Healthcare India over a patent infringement lawsuit concerning its fully liquid hexavalent vaccine, EasySix. The agreement stipulated that Sanofi would not commercially launch its vaccine, Shan6, in India and would withdraw oppositions against Panacea Biotec’s patent. Following the announcement, Panacea Biotec’s stock surged to a 52-week high of ₹349.79 per share. (moneycontrol.com)

UNICEF Contract for Polio Vaccine Supply

In December 2024, Panacea Biotec secured a contract from the United Nations International Children’s Emergency Fund (UNICEF) to supply 115 million doses of its bivalent oral polio vaccine (bOPV). The contract, valued at approximately $14.95 million, is set for execution in the 2025 calendar year. This development led to a 5% increase in the company’s share price, reflecting positive investor sentiment. (moneycontrol.com)

Global Vaccine Orders and Market Expansion

In October 2022, Panacea Biotec announced a $127.3 million contract from UNICEF and the Pan American Health Organisation for the supply of its pentavalent vaccine, EasyFive-TT. This vaccine offers protection against five severe diseases and underscores the company’s expanding role in global health initiatives. (moneycontrol.com)

Launch of EasyFourPol Vaccine in India

In December 2023, Panacea Biotec launched EasyFourPol, the world’s first fully liquid wP-IPV-based pentavalent vaccine, in India. This vaccine safeguards children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b. The launch was well-received, with the company’s share price rising by 5% following the announcement. (proinvestnews.com)

Joint Collaboration with Biopharma Inc.

In 2022, Panacea Biotec entered into a joint collaboration with Biopharma Inc., a U.S.-based generic pharmaceutical company. The partnership focuses on the development, licensing, manufacturing, supply, and sales of seven complex generic pharmaceutical products, with an estimated market potential exceeding $800 million. This collaboration marks Panacea Biotec’s strategic expansion into the biopharmaceutical manufacturing and sales sector. (biovoicenews.com)

Divestment of Domestic Formulations Business

In March 2022, Panacea Biotec Pharma Limited, a subsidiary of Panacea Biotec, agreed to sell its domestic formulations business to Mankind Pharma for ₹1,908 crore (approximately $252.4 million). This divestment aims to enhance liquidity, support investments in products under development, and expand capacities for key vaccine projects, aligning with the company’s strategic focus on global markets. (healthcaremea.com)

Stock Performance and Market Sentiment

Panacea Biotec’s stock has experienced significant volatility, with notable surges following major announcements. For instance, in September 2024, the stock reached a 52-week high of ₹349.79 per share after the patent settlement with Sanofi. Similarly, in December 2024, the share price increased by 5% following the UNICEF contract award. These movements reflect investor confidence in the company’s strategic initiatives and market positioning. (moneycontrol.com, moneycontrol.com)

Panacea Biotec’s recent developments underscore its commitment to innovation, global expansion, and strategic partnerships, positioning the company as a significant player in the biotechnology and pharmaceutical sectors.